Nasdaq Stockholm
Every company in the roster listed on Nasdaq Stockholm.
Every company in the roster listed on Nasdaq Stockholm.
11 of 11 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Active Biotech ABACTI · Nasdaq Stockholm | 1 asset: 1 Ph 2 | Naptumomab estafenatoxPhase 2 · Non-Small Cell Lung CancerWeak signal | 1 Mar 2027Naptumomab estafenatox · Phase 1 | — | — | — | — |
BioArctic ABBIOA B · Nasdaq Stockholm | 1 asset: 1 Ph 2 | exidavnemabPhase 2 · Parkinson's DiseaseWeak signal | None on record | — | — | — | — |
BioInvent International ABBINV · Nasdaq Stockholm | 1 asset: 1 Ph 2 | BI-1910Phase 1/2 · Non-Small Cell Lung Cancer | 14 Jul 2027BI-1910 · Phase 1/2 | —no price since 25 Sep 2026 | — | — | — |
Cantargia ABCANTA · Nasdaq Stockholm | 1 asset: 1 Ph 2 | NadunolimabPhase 1/2 · Non-Small Cell Lung CancerWeak signal | None on record | — | $24MMar 2026 | ~7.4 qtrs | — |
Hansa BiopharmaHNSA · Nasdaq Stockholm | 1 asset: 1 Ph 3 | ImlifidasePhase 3 · Chronic Kidney DiseaseWeak signal | 28 Feb 2027Imlifidase · Phase 2 | — | $71MMar 2026 | ~3.3 qtrs | ~$27M |
IRLAB TherapeuticsIRLAB A · Nasdaq Stockholm | 3 assets: 3 Ph 2 | Mesdopetam (IRL790)Phase 2 · Parkinson's DiseasePartial signal | None on record | — | — | — | — |
Medivir ABMVIR · Nasdaq Stockholm | 1 asset: 1 Ph 2 | BirinapantPhase 2 · Ovarian Cancer | None on record | — | — | — | — |
MendusIMMU · Nasdaq Stockholm | 1 asset: 1 Ph 2 | VididencelPhase 2 · Acute Myeloid LeukemiaWeak signal | 1 Sep 2029Vididencel · Phase 1 | — | $7.0MDec 2025 | Ended May 2026 | ~-$9.1M |
SanionaSANION · Nasdaq Stockholm | 1 asset: 1 Ph 3 | TesofensinePhase 3 · ObesityReliable signal | None on record | — | $63MDec 2025 | ~12.8 qtrs | — |
Swedish Orphan Biovitrum AB (publ)SOBI · Nasdaq Stockholm | 6 assets: 3 approved, 1 Ph 3, 1 Ph 2, 1 other | InotersenUS approval withdrawn · Transthyretin Amyloidosis with PolyneuropathyReliable signal | Mar 2027Olezarsen · Phase 3 | — | — | — | — |
Xbrane Biopharma ABXBRANE · Nasdaq Stockholm | 1 asset: 1 Ph 3 | Ranibizumab (Ximluci)Phase 3 · Age-Related Macular Degeneration | None on record | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.